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http://www.biomedcentral.com/1472-6882/13/191RESEARCH ARTICLE Open AccessEconomic analysis of complementary, alternative,
and integrative medicine: considerations raised
by an expert panel
Ian D Coulter1,2,3, Patricia M Herman1,4* and Shanthi Nataraj1Abstract
Background: An international panel of experts was convened to examine the challenges faced in conducting
economic analyses of Complementary, Alternative and Integrative Medicine (CAIM).
Methods: A one and a half-day panel of experts was convened in early 2011 to discuss what was needed to bring
about robust economic analysis of CAIM. The goals of the expert panel were to review the current state of the
science of economic evaluations in health, and to discuss the issues involved in applying these methods to CAIM,
recognizing its unique characteristics. The panel proceedings were audiotaped and a thematic analysis was
conducted independently by two researchers. The results were then discussed and differences resolved. This
manuscript summarizes the discussions held by the panel members on each theme.
Results: The panel identified seven major themes regarding economic evaluation that are particularly salient to
determining the economics of CAIM: standardization (in order to compare CAIM with conventional therapies, the
same basic economic evaluation methods and framework must be used); identifying the question being asked, the
audience targeted for the results and whose perspective is being used (e.g., the patient perspective is especially
relevant to CAIM because of the high level of self-referral and out-of-pocket payment); the analytic methods to be
used (e.g., the importance of treatment description and fidelity); the outcomes to be measured (e.g., it is important to
consider a broad range of outcomes, particularly for CAIM therapies, which often treat the whole person rather than a
specific symptom or disease); costs (e.g., again because of treating the whole person, the impact of CAIM on overall
healthcare costs, rather than only disease-specific costs, should be measured); implementation (e.g., highlighting studies
where CAIM allows cost savings may help offset its image as an “add on” cost); and generalizability (e.g., proper
reporting can enable study results to be useful beyond the study sample).
Conclusions: The business case for CAIM depends on economic analysis and standard methods for conducting
such economic evaluations exist. The challenge for CAIM lies in appropriately applying these methods. The
deliberations of this panel provide a list of factors to be considered in meeting that challenge.
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Why should we care about the economics of comple-
mentary, alternative and integrative medicine (CAIM)?
Healthcare is expensive and becoming more so every
year. Policy and decision makers increasingly need in-
formation on costs, as well as effectiveness and safety,
in order to formulate healthcare strategies that are
both clinically effective and financially responsible. In
addition, a report prepared for the 2009 Institute of
Medicine (IOM) Summit on Integrative Medicine and
the Health of the Public notes that “[b]oth clinical
effectiveness and cost effectiveness are required to for-
mulate evidence-based policy [1] (p. 3)”. If CAIM is to
be considered in health care policy and reimbursement
decisions, its economic impact must be determined.
Methods
On January 26 and 27, 2011, RAND Corporation, in col-
laboration with the Samueli Institute, convened a panel
of experts to discuss what was needed to bring about ro-
bust economic analysis of CAIM. The goals of the expert
panel were to review the current state of the science of
economic evaluations in health, and to discuss the issues
involved in applying these methods to CAIM, recogniz-
ing its unique characteristics. The panel was chosen in
consultation with the Samueli Institute and was com-
prised of eleven scholars with experience in applied
health economics in general, the economic analysis of
CAIM in particular, and/or CAIM research.
Prior to convening the panel, a background paper was
developed that summarized the state of the science with
respect to economic evaluation of CAIM, and a list of
example published studies compiled using a simple
search strategy of “complementary therapies” AND “cost
benefit analysis”. Studies that were full economic evalua-
tions (i.e., those that presented costs and benefits for
two or more options), or whose study designs illustrated
some aspect that might be particularly relevant to CAIM
(e.g., incorporating patient preferences into the alloca-
tion process) were included in the list. This background
paper and list of example studies were circulated among
panel members, and their comments and feedback were
incorporated prior to the meeting. These revised docu-
ments (available upon request from the corresponding
author) were then redistributed to panel members for
their use at the meeting.
The one and a half-day panel meeting was held at
RAND Corporation offices in Santa Monica, California.
The morning of the first day of the panel involved general
discussion about economic evaluation and its application
to CAIM. Discussions during the afternoon of the first
day and morning of the second day were framed around
a ten-point checklist for assessing economic evaluations
in health care from Drummond et al [2]. Based on panelmember input, we developed a matrix of issues to be
considered for each item on this checklist with em-
phasis on issues that are unique or particularly salient
to CAIM. This matrix was used as a guide for panel
discussions on the morning of the second day. We used
an audiotape to record the panel proceedings during
both days.
Following the panel, the authors conducted a thematic
analysis, in which two researchers independently listened
to the audiotape, listed the topics that were discussed,
and grouped the topics into themes. The themes were
then discussed and agreed upon, and panel members’
discussions on each summarized. A report was written
on the results of the panel and circulated to the panel
members for comment and revisions. This article pre-
sents a summary of the themes discussed and recom-
mendations made to CAIM researchers interested in
economic evaluation.Results
Background on economic evaluations
Since the panellists were generally not experts in eco-
nomic evaluation, the background paper and a fair
amount of the panel discussion was spent summarizing
and reviewing its main points. These points are briefly
reviewed here.
Drummond et al. [2] define an economic evaluation as
“the comparative analysis of alternative courses of action
in terms of both their costs and consequences”. (p. 9)
Consequences can include economic, clinical, and human-
istic outcomes [3]. The specific costs and economic out-
comes that should be included depend on the perspective
from which the evaluation is conducted, and may include
direct medical costs (such as practitioner fees or drug
costs), direct non-medical costs (such as travel costs asso-
ciated with receiving the therapy), and indirect costs (such
as lost worker productivity). Clinical and humanistic out-
comes can collectively be called health outcomes and are
measured in effectiveness trials. The form in which health
outcomes are reported determine the type of economic
evaluation performed.
There are three main types of “full” economic evalua-
tions. Full economic evaluations compare the costs and
consequences of two or more alternatives. Partial evalua-
tions only compare costs, or report costs and conse-
quences for only one option.Cost-effectiveness analysis (CEA)
This type of study measures the costs and economic
consequences of a therapy in monetary units, and clin-
ical outcomes in “natural” units, such as the amount by
which cholesterol is lowered, or the number of life-years
saved.
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Like a CEA, a CUA measures costs and economic con-
sequences in terms of monetary units. However, health
outcomes are reported in terms of a measure of overall
health such as quality-adjusted life-years (QALYs).
QALYs account for both morbidity and mortality by
weighting life-years by the health-related quality of life
in those years [4].
Cost-benefit analysis (CBA)
A CBA measures costs, economic consequences and
health outcomes all in monetary terms. Monetary values
for health outcomes can be estimated by using a variety
of methods, including those that elicit willingness-to-pay
(WTP) for the outcome.
The main advantage of conducting a CEA, rather than a
CUA or CBA, is that these studies can use the clinical out-
come measured during the effectiveness trial. However,
CEA is less helpful if the treatments being compared do
not affect the same health outcomes. CEA is most use-
ful when comparing treatments that have the same one-
dimensional goal—e.g., a reduction in glycosylated
hemoglobin (HbA1c) [2]. CUA and CBA analyses ad-
dress this issue by measuring health outcomes in terms
of more general units (e.g., QALYs in case of CUA andTable 1 Summary of discussion themes and recommendation
Themes Recommendations
1. Standardization ●In order to compare CAIM with convent
methods must be used.
2. The question, audience, and
perspective
●Given the high level of self-referral and o
outcomes and relevant costs should be in
or as part of the societal perspective when
3. Analytic methods ●Both the treatment and usual care arms
treatment across practitioners.
●To capture the preventive nature of CAIM
impacts beyond the treatment phase.
4. Outcomes ●Given the tendency for CAIM to treat the
report a wide range of outcomes, and/or
range such as quality-adjusted life-years (Q
●If multiple outcomes are used, consider
5. Costs ●Given that CAIM is not often covered by
the cost data available to studies of conve
data (e.g., practitioner records or patient s
●Since CAIM therapies tend to treat the w
Therefore, it is recommended that overall
specific costs.
6. Implementation ●Highlighting studies where (and the circ
reduce costs (rather than increase costs, ev
policy makers.
7. Generalizability ●The first recommendation made under t
enable study results to be adapted to oth
●As compared to conventional therapies,
robustness of results given the large variab
●Given that patient beliefs can have a larg
measured and reported to allow comparismonetary terms in the case of CBA), which allow compar-
isons to be made across therapies that affect different
aspects of health.
Panel themes and recommendations for each
In this section, we present a summary of the main issues
discussed during the panel. The seven major discussion
themes (listed in Table 1 and discussed below) are the
result of thematic analysis of the panel proceedings. To in-
crease the usefulness of these results to researchers inter-
ested in CAIM economic evaluation, references are given
for some points made by the panel, and the authors have
included additional information from the literature (noted
as such) to further expand on others.
1. Standardization
During the panel, there was a substantial amount of
discussion about whether the methods used to perform
economic evaluations of conventional healthcare options
were appropriate for CAIM. In the end, the panellists
generally agreed that in order to compare CAIM with
conventional therapies, the same basic economic evalu-
ation framework and methods must be used. They noted
that currently there is a tendency for medical practitionerss made by the panel
ional therapies, the same basic economic evaluation framework and
ut-of-pocket payment the patients’ perspective as to important health
corporated into CAIM economic evaluations either as a separate analysis
that perspective is used.
of CAIM trials should be described in detail given the heterogeneity of
, longer follow ups and/or modeling should be used to capture
whole person, rather than only the targeted condition, measure and
to use a summary measure of overall health that could capture the full
ALYs).
reporting these as a cost-consequence analysis.
health insurance (whose claims databases are the source of much of
ntional medicine) and since the relative quality of other sources of cost
elf-report) is not always clear, both sets of costs could be reported.
hole person they may have cost impacts beyond the targeted disease.
healthcare costs be reported, either in addition to or instead of disease-
umstances under which) CAIM can both improve health outcomes and
en if still considered cost effective) might gain it more attention from
heme 3 above is reiterated here; this information is also needed to
er settings.
CAIM therapies might require more sensitivity analyses to test the
ility in treatment methods, dosages, and pricing.
e impact on outcomes, especially in CAIM, these beliefs should be
ons to other populations.
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rather than on evidence. In order to integrate CAIM and
conventional medicine, CAIM therapies will need to dem-
onstrate success in some comparable way. Moreover, the
panel noted that many of the issues discussed here also
apply to evaluations of conventional medicine.
2. The Question, Audience, and Perspective
The panellists agreed that, similar to what is done in
economic evaluations of conventional medicine, before
beginning a study, it is crucial to determine the ques-
tion that the study is intended to answer and whom
that answer is intended to inform (i.e., the audience).
The question will determine which alternatives to
compare and the audience will determine the perspec-
tive of the evaluation. As discussed above, the perspec-
tive of the analysis determines which costs will be
included. For example, if the purpose of an economic
evaluation is to provide information to a health plan
on the benefits of providing coverage for acupuncture
for headache pain, the comparison should be between
acupuncture and the therapies the plan now covers for
headache, and the perspective should be that of the
health plan—also known as the third-party payer
perspective. Since the payer perspective is used, direct
medical expenses that would be reimbursed by the
payer would be included, but out-of-pocket expenses
(including co-pays or deductibles) and travel costs in-
curred by patients would not. Panel members also
noted that whenever possible, an economic evaluation
should document costs to allow for analyses appropri-
ate for more than one audience (i.e., from more than
one perspective).
One issue noted by the panel as specific to CAIM, but
also increasingly relevant for all of healthcare, is eco-
nomic evaluation from the patient perspective. In
practice, this means that the costs to the patient (e.g.,
out-of-pocket costs and travel and time costs involved
with receiving the treatment) and the benefits of im-
portance to patients are included in a separate analysis
showing the patient perspective, and/or that all patient
costs are included in the societal perspective. The pa-
tient perspective is especially relevant to CAIM because
so much of CAIM is accessed directly through patient
self-referral and paid out-of-pocket. Therefore, the pa-
tient’s perception of whether the benefits of care exceed
its cost is important.
Additional information: It should be noted that the
patient perspective is assumed to be included in eco-
nomic evaluations from the societal perspective. The
patient perspective is, for the most part, ignored in eco-
nomic evaluations of conventional medicine. This lack
of focus on the patient perspective could explain theinconsistencies seen in conventional evaluations using
the societal perspective [5-7].
3. Analytic Methods
As discussed above, the panel generally agreed that the
same methods should be used to evaluate conventional
therapies and CAIM, though the methods may need to
be tailored to better fit the latter. Along these lines, the
panel discussed the challenges inherent in determining
the effectiveness of CAIM since evidence of effectiveness
is a required input for economic evaluation.
Panel members noted that historically, a significant
amount of CAIM research funding has been provided
for trials that illuminate the mechanism through which a
therapy affects health outcomes—i.e., efficacy trials.
More recently, however, research has begun to focus
first on whether a therapy is effective, and then only
consider the mechanisms through which it might work
once it has been proven effective; however, this remains
a controversial area.
Related to the real world focus of an effectiveness trial
(and economic evaluation), the comparator also must
represent a real world option such as “usual care”; pla-
cebo is rarely an appropriate comparator. However,
panel members acknowledged that defining “usual care”
could present a challenge for certain CAIM therapies such
as chiropractic. In some cases chiropractic is already con-
sidered to be part of “usual care,” so if the treatment is to
provide chiropractic services, it would be unclear how to
define “usual care” in the control arm.
The panel agreed that the definition of the treatment
arm also offers special challenges in CAIM. Care processes
may differ drastically across practitioners, even more so
than in conventional medicine. Therefore, it might be im-
portant to explore practitioner and treatment heterogen-
eity, and to document during the trial the characteristics
of the treatment actually provided (i.e., treatment fidelity
[8]). This documentation is important both to better com-
municate to others what happened during the study, and
to increase the ability to replicate the results. Several panel
members advocated the use of qualitative methods, in-
cluding observational studies and ethnographic observa-
tion, to provide information about the care process [9].
Finally, panel members generally agreed that given the
prevention focus of much of CAIM, it would be desirable
to use a relatively long timeframe to measure outcomes.
Additional information: There has been much written
on the challenges of measuring the health impacts of
CAIM [10-13]. Because full economic evaluations require
estimates of both costs and health impacts, these chal-
lenges will also apply to economic evaluations of CAIM.
Note that an economic evaluation requires a measure of
effectiveness; not efficacy. Efficacy “denotes how well the
Coulter et al. BMC Complementary and Alternative Medicine 2013, 13:191 Page 5 of 9
http://www.biomedcentral.com/1472-6882/13/191intended objectives are realized in ideal settings”, while ef-
fectiveness can be defined as “the extent to which [health
improvements are achieved] in real practice settings [14]”.
Comparative Effectiveness Research (CER) has placed
a new focus on effectiveness, and it has been given
added weight by funding through NIH and in particular
AHRQ (Agency for Healthcare Research and Quality)
[9]. CER has variously been described as including prag-
matic trials, head to head trials, and real world trials
[15-19]. This trend may be especially important for
CAIM therapies that are already in common use, even
though the mechanisms through which they work may
be poorly understood by the medical community.
Unfortunately, given the need for longer trials to cap-
ture the preventive nature of CAIM, trial participants
are generally only followed for one year or less [20].
However, longer-run results can be estimated through
modelling (see Herman et al. [21] for an example, and
Briggs et al. for an overview of modelling methods [22]).
4. Outcomes
Because CAIM tends to address the whole person rather
than target a specific symptom or disease, the panel
discussed how it can have a broad range of impacts on
(and beyond) health. As discussed above, CEAs (the most
common form of economic evaluation) are reported as a
monetary amount per some unit of health outcome, such
as the cost per percentage point reduction in HbA1c for
therapies targeting diabetes. One challenge identified by
the panel for CAIM is that standard CEA methodology
would allocate all costs to just one of what could be many
different types of health (and non-health) effects seen with
CAIM. For example, a CAIM therapy targeting diabetes
may not only lower HbA1c, but also improve blood lipids,
sleep, and overall energy. Reporting the cost-effectiveness
of this CAIM therapy only in terms of a cost per point re-
duction in HbA1c would ignore all its other benefits and
needlessly penalize this therapy in comparisons. Therefore,
it is important to measure and report a wide range of out-
comes, and/or to use a summary measure of overall health
that could capture the full range such as quality-adjusted
life-years (QALYs).
The panel also considered the possibility of develop-
ing or using an overall outcome measure that is specific
to CAIM. However, two objections were raised. First,
although several scales that may be more appropriate
for CAIM therapies, such as the Measure Yourself
Medical Outcome Profile (MYMOP) and the Arizona
Integrative Outcomes Scale (AIOS), have been devel-
oped, it is not currently possible to easily translate
these latter measures into QALYs—i.e., no preference
weights exist for these measures. Second, if the goal
is to compare CAIM to usual care, then it will benecessary to use a measure that will enable comparison
with conventional therapies.
The panel discussed a number of outcomes that could
be considered in economic evaluation of CAIM. Recogniz-
ing the importance of the patient perspective makes the
practices and outcomes valued by the patient more crit-
ical. It should be noted that the benefits of care to the
patient may extend beyond health improvement for the
condition of interest, and beyond health improvement in
general. For example, patients may derive value from the
process of care—aka process utility [23,24]. This may
come through a valued relationship with their practitioner,
or through the self-empowerment achieved by actively im-
proving their health. It was deemed unclear as to whether
effects on the patient’s family should be considered. These
additional patient benefits can be missed if the context
and goals of CAIM and the patient perspective are not
considered. The panel also noted that standard outcome
measures such as QALYs may present a challenge, as this
measure may mean little to patients. One panel member
suggested that using methods such as conjoint analysis
(i.e., a set of techniques to measure individuals’ prefer-
ences and tradeoffs across options [25]) could be helpful
in measuring a broad range of outcomes.
The panel also discussed a number of other outcome
measures that could be considered. These include: non-
medical outcomes such as overall quality of life (rather
than only health-related quality of life as is found in
QALYs) or increased worker retention; risk of future
events (e.g., cardiovascular events) estimates could provide
a substitute for extending study duration to measure
actual incidence; equity (i.e., fairness) such as whether an
underserved group receives access to a therapy; and modi-
fiable genetic markers.
Additional information: Quality-Adjusted Life-Years
(QALYs) provide a summary measure of overall health by
combining health-related quality of life with length of life.
A CUA is an economic evaluation that compares cost to
some measure of “utility” (roughly, overall satisfaction
with health) such as a QALY. The panel discussed the fact
that if QALYs are used to measure outcomes, then
researchers should carefully choose the most appropriate
instrument. The two QALY measures used most often in
economic evaluations of CAIM [5,20] are the EQ-5D [26]
and the SF-6D [27,28]. The SF-6D is calculated using a
subset of items from either the SF-36 [27] or SF-12 [28]
instruments. The EQ-5D appears to be less sensitive to
changes in the upper end of the health utility range (i.e.,
it exhibits ceiling effects), while the SF-6D appears to be
less sensitive in the lower end of the health utility range
(i.e., it exhibits floor effects) [29]. Therefore, the SF-6D
may be more sensitive to changes in health for popula-
tions who are generally well—the populations often
targeted by CAIM.
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be included in an economic evaluation see Bonomi
et al., 2005 [30].
One form of reporting an economic evaluation with a
wide range of outcomes is called a cost-consequence
analysis (CCA). A CCA allows decision makers to select
from a list the components of costs and health benefits
most relevant to their perspective and needs [2,31,32].
Basically, instead of (or in addition to) reporting an in-
cremental CEA or CUA ratio, the economic evaluation
reports estimates for each cost component (e.g., direct
outpatient visit costs, medication costs, participant travel
costs, indirect/productivity costs, etc.) and for each
health effect (e.g., improvement in each biomarker, stress
reduction, increase in self-efficacy, changes in quality of
life, absentee days reduced, QALY gains, etc.) for each
arm of the study. See Dzator et al., 2004, for an example
[33]. This approach may be important for CAIM for two
reasons. First, it allows measurement and acknowledg-
ment of a full range of health (and non-health) impacts
seen in CAIM [34]. Second, some authors believe that this
method of reporting outcomes may improve decision
makers’ use of economic information [31].
5. Costs
The panel identified a number of challenges that arise
when measuring costs for CAIM therapies. First, in con-
trast to conventional medicine where allowed charges
tend to be dictated by health plans, the prices charged
for CAIM therapies tend to be more heterogeneous, and
typical or average prices on an aggregate (e.g., state or
national) basis are generally unknown.
Second, since CAIM therapies are typically not covered
by insurance plans, claims data—the source of cost data for
most economic evaluations of conventional medicine—are
not generally available for the CAIM therapy under study.
Options to overcome the lack of claims data include
patient-reported costs or practitioner-generated medical
or clinic records. Panel members indicated that there are
potential drawbacks to both methods. Resource use (cost)
data reported by patients and practitioners often do not
agree, and it is not clear which should be viewed as more
accurate. This issue is compounded by the fact that prices
are heterogeneous for CAIM services, so it is difficult to
determine a reasonable range for cost data. In addition, a
good coding of disease states is needed in order to accur-
ately ascribe costs. CAIM disease classifications (many of
which are derived from non-Western traditional practices)
may not follow conventional classifications.
The panel suggested that if both patient and practitioner
data are available, and it is not clear which is more accur-
ate, both sets of costs could be reported in the study, one
as the base case and the other in a sensitivity analysis. Inaddition, it is also possible to use expert opinion as a
source of cost data.
One issue that arises in all economic evaluations is
whether to include overall (all) healthcare costs, or only
disease-specific costs for the targeted condition [5,35].
The panel agreed that overall costs would be more rele-
vant to CAIM studies, since these therapies tend to treat
the whole person rather than a specific symptom or dis-
ease. The panel recommended that all costs that could
be measured within the study budget should be included
in the study.
6. Implementation
There were several discussions regarding implementa-
tion: how study results are translated into practice. Panel
members noted that it takes a long time for evidence to
change practice and that this might present an especially
large barrier for CAIM since it is, by definition, outside
the conventional healthcare system. One discussion cen-
tered on the question of whether the cost-effectiveness of
a therapy actually makes a difference in policymaking.
Panellists believe that highlighting CAIM therapies that
can produce cost savings, versus those that might be
considered cost-effective (i.e., improve health, but also
increase costs), might be particularly important to gain
attention in the policy context.
Related to this topic, economic evaluation offers the
opportunity to determine whether a CAIM therapy is
complementary (i.e., is an “add-on” to) conventional care
or alternative (i.e., replaces it). It is not always clear
whether a particular therapy will be used as a replacement
for, or in addition to, usual care, and the cost-effectiveness
of the therapy can differ depending on how it is used. For
example, a study of several CAIM therapies commissioned
by the National Institute of Complementary Medicine
(NICM) in Australia found that acupuncture was cost-
effective for chronic low-back pain when used as a com-
plement, but not as a substitute, for standard care [36].
7. Generalizability
During a number of the discussions regarding costs,
outcomes, and other topics, the issue of generalizability
was mentioned. Panellists indicated that there is a lack of
standardization among CAIM therapies: for example,
what constitutes an acupuncture treatment can vary
widely between practitioners and even between patients of
the same practitioner. The panel recommended consulting
a representative body for the therapy being studied to de-
velop an idea of what the profession considers reasonable
treatment. They also emphasized the need to document
the treatments that are actually performed during a study,
in order to enable others to replicate the treatment.
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tional and CAIM medicine involve complex treatments
even though this might not be as evident in conventional
medicine. This is because most trials only look at changing
one component of a complex treatment at a time. When
comparing conventional and CAIM treatments, a whole
systems approach may be necessary to capture complexity
on both sides. Similarly, in describing the treatment and
control groups, it may be necessary for the researcher to
supply some background on the two different systems of
care under which they are provided. The systems of care
may differ not only in the treatments they use, but also in
terms of the cultural, professional, political, and economic
context in which the treatments are provided. For ex-
ample, whether the care is provided in a for-profit versus
not-for-profit environment, the professional culture of the
practitioners, and the traditional context of providing
treatment may also be important.
One panel member also pointed out that since a “usual
care” control group should reflect current practices, which
may differ across care settings, the intended audience of
the study could also affect the type of care provided in the
control arm. The panel agreed that regardless of which op-
tion is chosen, and for transferability, it is important that
the study fully document what care was actually provided
in both arms of the trial.
To address the issue of transferability (“generalizability”),
the panel provided several recommendations. First, since
costs and delivery methods vary greatly, the economic
evaluation should at least list disaggregated costs, and
should present separate values for the amount of each re-
source used and the cost of the resource, so that different
audiences can tailor the cost estimates to their settings.
Second, the Panel on Cost-Effectiveness in Health and
Medicine [14,37] recommended that all economic evalua-
tions conduct sensitivity analyses to test the robustness of
the results. The panel convened by RAND and the
Samueli Institute suggested that CAIM therapies might re-
quire more sensitivity analyses than conventional therapies
given the large variability in treatment methods, dosages,
and pricing. Third, panel members discussed the idea of
heterogeneity among patients. One specific source of het-
erogeneity mentioned was that of beliefs. Patient beliefs
may play a role in effectiveness [11,38-42]. Since the
beliefs of patients enrolled in an effectiveness trial may be
different from those in the population as a whole, the out-
comes measured in the study may not be generalizable to
the population. The panel recommended that targeting a
heterogeneous population for an effectiveness trial could
be helpful, since it would allow researchers to test the ro-
bustness of the effects across different types of patients,
and might allow a subgroup analysis to be performed.
Finally, the importance of scalability was also discussed;
panel members indicated that treatment costs could beeither higher or lower if the treatment were implemented
on a large scale.
Additional information: Although health outcomes are,
to some extent, considered generalizable across settings,
economic outcomes usually are not [43]. This may be be-
cause human physiology and psychology are more consist-
ent and replicable across locations and settings than are
resource availability, practice patterns and relative prices.
Because of this, one goal in economic evaluation is to en-
sure the transferability of study results—i.e., to provide
enough study detail so that results can be adapted (usually
via modeling) to other settings [44]. Studies have shown
that the aspect of setting which has the most effect on
costs is unit price [45]. Fortunately, the problem of price
variation across settings is the easiest to handle methodo-
logically, through the separate reporting of resource use
and unit costs [46,47].
In contrast to the provision of a specific drug or ther-
apy to treat a specific symptom, much of CAIM consists
of complex treatments that address the whole person.
Beckman et al. [48] and Bell et al. [49] have argued that
this contrast necessitates the use of a systems theory
approach to study not just health outcomes, but overall
wellness along multiple (bio-psycho-socio-spiritual) di-
mensions as well as the relationship between the patient
and the practitioner. In a similar vein, Ritenbaugh et al.
[50] and Verhoef et al. [51] have advocated the use of
whole systems research, which “encompasses investiga-
tion of both the processes and the outcomes of complex
health care interventions [50]”.
Discussion
Economic analysis of CAIM will become increasingly
important as the healthcare system struggles to contain
costs. Traditionally CAIM providers have developed a
direct-to-patient fee-for-service economic model that
has sustained their development and growth. Much of
integrative medicine has depended extensively on phil-
anthropy and research grants to fund its growth [52].
But CAIM will increasingly face the challenge of finding
a sustainable economic model; in addition, as CAIM
therapies compete more with biomedicine and each
other, they will need economic analysis, along with evi-
dence about efficacy and effectiveness, to support their
inclusion in health care systems and funding programs.
This study has several limitations. The first is that al-
though RAND and Samueli Institute staff were successful
in assembling a wide range of experts for the panel, the
results of the panel are still limited by who did (and did
not) participate. Related to this, the topics included in this
paper are limited by those topics the panel raised and
chose to discuss. Finally, although the background paper
and list of example studies met their intent of providing a
common starting place for panel members regarding their
Coulter et al. BMC Complementary and Alternative Medicine 2013, 13:191 Page 8 of 9
http://www.biomedcentral.com/1472-6882/13/191discussions, by necessity they could not provide an
exhaustive education on economic evaluation to those
who were CAIM researchers, nor one on CAIM for those
well-versed in economics. Therefore, likely more time
than originally intended in the limited panel schedule was
spent on mutual education. However, it is possible that
this mix is also responsible for themes and recommenda-
tions that would not otherwise have come up.
Conclusions
Absent evidence of economic impacts, it is difficult to
see how the business case can be made for CAIM. The
methods for economic analysis exist. The challenge for
CAIM lies in appropriately applying these methods.a The
deliberations of this panel provide a list of factors to be
considered in meeting that challenge.
Endnote
aIn response to this panel and its outcomes the
Samueli Institute has published a handbook describing
the methods needed for the economic evaluation of
CAIM. It is titled “Evaluating the Economics of Comple-
mentary and Integrative Medicine”, and is available
from Amazon.
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